Form 4: Invivyd CSO Sells Shares for Tax Obligations

Invivyd's Chief Scientific Officer, Robert D. Allen III, sold a portion of his common stock to cover tax liabilities following the vesting of restricted stock units.

Summary

• Robert D. Allen III, Invivyd, Inc.'s Chief Scientific Officer, reported transactions involving the company's common stock.
• On February 15, 2026, 99,000 restricted stock units (RSUs) vested, converting into 99,000 shares of common stock.
• Following the vesting, Mr. Allen's beneficial ownership of common stock increased to 152,068 shares.
• On February 17, 2026, Mr. Allen sold 18,189 shares of common stock at a weighted average price of $1.5396 per share.
• On February 18, 2026, an additional 19,392 shares of common stock were sold at a weighted average price of $1.5778 per share.
• These sales were non-discretionary 'sell-to-cover' transactions executed to satisfy tax withholding obligations upon RSU vesting, pursuant to a Rule 10b5-1 plan adopted on February 20, 2025.
• After these transactions, Mr. Allen beneficially owns 114,487 shares of common stock.
• The RSU award vests over an eighteen-month period, with one-third vesting every six months following the grant date of February 15, 2025, subject to continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine, pre-planned 'sell-to-cover' sales for tax purposes, which are common for executives receiving equity compensation and do not necessarily reflect a change in management's outlook on the company's future.

Negatives

• The sale of shares by a Chief Scientific Officer, even for tax purposes, reduces insider ownership, which can sometimes be perceived negatively by the market.

Future Outlook

The RSU award is structured to vest over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, contingent on the Reporting Person's continuous service.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions, where executives sell shares to cover tax liabilities upon the vesting of equity awards, are a common and routine practice in the industry. These transactions are frequently pre-arranged under Rule 10b5-1 plans to avoid accusations of insider trading.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, though the pre-planned, tax-related nature of the sale mitigates concerns about discretionary selling.

Next Steps

• Remaining tranches of the RSU award will continue to vest every six months following the February 15, 2025 grant date, subject to the Reporting Person's continuous service.

Key Dates

Recommendation

The reported transactions are non-discretionary 'sell-to-cover' sales to satisfy tax obligations upon RSU vesting, executed under a pre-arranged Rule 10b5-1 plan. This is a routine event for executives receiving equity compensation and does not typically signal a change in the company's fundamentals or management's long-term confidence. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter an investment thesis.

Keywords

Invivyd, IVVD, insider transaction, Form 4, stock sale, restricted stock units, RSU, sell-to-cover, executive compensation, Rule 10b5-1